Author:
Matondo Abel,Jo Yong Hwa,Shahid Muhammad,Choi Tae Gyu,Nguyen Minh Nam,Nguyen Ngoc Ngo Yen,Akter Salima,Kang Insug,Ha Joohun,Maeng Chi Hoon,Kim Si-Young,Lee Ju-seog,Kim Jayoung,Kim Sung Soo
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Jemal, A. et al. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57, 43–66 (2007).
2. Cannistra, S. A. Cancer of the ovary. New England Journal of Medicine 351, 2519–2529, doi: 10.1056/NEJMra041842 (2004).
3. McGuire, W. P. et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Seminars in Oncology 23, 40–47 (1996).
4. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 334, 1–6, doi: 10.1056/NEJM199601043340101 (1996).
5. Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. Journal of Clinical Oncology 26, 5284–5293, doi: 10.1200/JCO.2008.18.1107 (2008).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献